Innovating Works

HDPR

Desconocido
TACT: Targeted Anti Cancer Therapies HEIDELBERG PHARMA RESEARCH GMBH participó en un H2020 H2020-MSCA-ITN-2019 Antibody-Drug Conjugates (ADCs) are fast growing classes of oncology therapeutics. They consist in a highly potent cytotoxic drug connected...
2020-02-05 - 2024-03-31 | Financiado
Magicbullet Reloaded: Small Molecule Drug Conjugates for Targeted Delivery in Tumor Therapy HEIDELBERG PHARMA RESEARCH GMBH participó en un H2020 H2020-MSCA-ITN-2019 "Despite the continuing development of new and more efficient treatments, cancer remains the second cause of premature death worldwide. Mult...
2019-09-11 - 2024-04-30 | Financiado
INTEGRATA: Integrating chemical and biological approaches to target NAD production and signaling in cancer HEIDELBERG PHARMA RESEARCH GMBH participó en un H2020 H2020-MSCA-ITN-2018 Deregulated nicotinamide adenine dinucleotide (NAD) biosynthesis and signaling underlies many aspects of carcinogenesis. NAD biosynthetic en...
2018-09-13 - 2023-04-30 | Financiado
pHioniC: pH and Ion Transport in Pancreatic Cancer HEIDELBERG PHARMA RESEARCH GMBH participó en un H2020 H2020-MSCA-ITN-2018 PHioniC brings together highly synergistic expertise, research and training facilities to investigate pancreatic ductal adenocarcinoma (PDAC...
2018-08-17 - 2023-06-30 | Financiado
MAGICBULLET: Peptide Drug Conjugates for Targeted Delivery in Tumor Therapy HEIDELBERG PHARMA RESEARCH GMBH participó en un H2020 H2020-MSCA-ITN-2014 Many tumor cells are characterized by the overexpression of certain antigens. Molecules that specifically recognize these structures are sui...
2014-12-05 - 2018-12-31 | Financiado
* Datos extraídos de la documentos o webs disponibles en diferentes organismos públicos.